Big Pharma Case Study

1052 Words 5 Pages
Register to read the introduction… Sub-Saharan Africa’s AIDS coverage is still low (37%) and many people are in need of treatment (10.6M in 2009). This constitutes a huge market to target, all the more since Cipla’s ”Trimune” remains the cheapest available AIDS treatment. In order to gain more influence in those countries, they will have to sign new partnerships with Non-Profits or to manage to directly address patients instead of negotiating with governments. Eventually, they should invest more in research if they want to compete with “Big pharma” future patents and keep a significant market share in India. This country must remain their “cash cow” by developing drugs dedicated to low income people and communicating on Cipla’s local footprint (partnerships with doctors, …show more content…
Their contribution to solve AIDS crisis should mainly rely on efficient R&D to find medicines able to slow down or to fight AIDS development. They could also dedicate some of their profits to create foundations dedicated to emerging countries whose development is affected by AIDS or other infectious diseases; * “Rich countries” governments should go on helping pharmaceutical companies to develop efficient drugs. But this help could be subject to constraints in terms of price, patent duration and delivery systems. The idea is that AIDS medicine should become a “common good” accessible to anybody. This is a matter of humanity; * NGOs should continue to focus a lot on prevention, especially in emerging countries where religious fundamentalism become more and more influent. They could be the intermediaries between local governments, pharmaceutical companies and western governments as they have the required know-how to select and administrate drugs efficiently. They might be involved in the R&D process by sharing best practices in terms of delivery system for

Related Documents